Breast cancer
Theragnostic testing – choosing the right therapy in mTNBC

Ananya (35 years old)

Ananya, 35 years old, works part-time as a shop assistant in a boutique. She was diagnosed with breast cancer 2 years ago, and she likes helping women who are fighting cancer as well by making them feel beautiful and comfortable in their clothes. Now, Ananya is diagnosed with mTNBC.

Assessment summary

  • Premenopausal
  • Genetic testing: no BRCA1/2 or PALB2 pathogenic variants
  • No comorbidities
  • ECOG PS: 0
  • Medical history
    • 2 years ago: diagnosis early stage TNBC (cT1N1M0)
      • Enrolled in clinical trial, treated with 4 cycles of pembrolizumab + paclitaxel + carboplatin, followed by 4 cycles of pembrolizumab + doxorubicin + cyclophosphamide
      • Unilateral mastectomy + ALND (pCR: ypT0 ypN0)
      • 9 cycles of pembrolizumab (treatment was tolerated)
  • Today, 1 year after completion of adjuvant pembrolizumab, CT scan of the chest and abdomen revealed 2 liver lesions and 1 suspicious lung lesion
    • Biopsy (liver lesion)
      • Breast cancer, ER 0%, PgR 0%, HER2 IHC 0, Ki67 40%, G2
      • PD-L1 status: CPS 15, IC score 0%

Which of the following treatment options would you choose for this patient?